ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2020

Jan 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2020-01-01

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-01	Common Stock	A	900000	$0.00	Acquired	2705237	Direct

Footnotes

F1: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of nine predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that must be achieved within five years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole.

F2: Includes a total of 1,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.